At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 301 enrolled
Drug / intervention
AbobotulinumtoxinA +1 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of a New Dilution and Injection Volume of AbobotulinumtoxinA for the Treatment of Moderate to Severe Glabellar Lines
In Brief
A Phase 3 clinical trial evaluating AbobotulinumtoxinA and Placebo for Glabellar Frown Lines. Completed, enrolled 301 participants across 11 sites.
Detailed Summary
An interventional phase 3 study to evaluate efficacy and safety of a new dilution and injection volume of AbobotulinumtoxinA treatment for glabellar lines
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsGlabellar Frown Lines
CountriesUnited States
Collaborators--
Timeline
Phase 3CompletedFinished
2020202120222023202420252026
First PostedMay 2019
Enrollment StartJun 2019
Primary CompletionSep 2019
Study CompletionApr 2020
TodayJul 2026
First PostedMay 23, 2019
Enrollment StartJun 17, 2019
Primary CompletionSep 27, 2019
Study CompletionApr 16, 2020
TodayJul 2, 2026
Enrollment to primary: 3 monthsPosted 7.1 years ago
Interventions
AbobotulinumtoxinAbiological
Treatment of glabellar facial lines with 50 U AbobotulinumtoxinA
Placeboother
Treatment of glabellar facial lines with placebo